Metabolically-fit Immunotherapies Portfolio

Description:

M23-139L – Inducing or Rescuing Glycolysis in Cancer Cells. Compositions that selectively block glycolysis in cancer cells while simultaneously enable glycolysis in non-cancer cells, such as macrophages, T cells, NK cells, etc. Vaccine formulations have been developed and tested on mice with positive results. Please see the published PCT (WO2024151709A1) for additional information.
 
M20-083L - Central Carbon Metabolite Based Polymers for Immunotherapy. Compositions to rescue immune cells from metabolic inhibition. Shown, through in vitro and in vivo experiments, to rescue activation and glycolysis of dendritic cells in the presence of a glycolysis pathway inhibitor. Can be used in conjunction with metabolic inhibitors in cancer therapeutics, as well as in conditions where there is a need for increased metabolism of immune cells. Please see the published US nonprovisional application (US20230058160A1) for additional information.
 
M20-082L - Central Carbon Metabolite Based Polymers for Tissue Regeneration. Composition and methods of making said compositions for accelerated wound healing and tissue regeneration. Testing of the compositions in mice showed accelerated wound healing by reducing the activation of immune cells in the wound bed. Please see the published US nonprovisional application (US20220411360A1) for additional information.
 
M20-015L - Metabolic Reprogramming of Immune Cells. Compositions for modulating immune responses to treat diseases in which there is inflammation-induced tissue damage, e.g.: autoimmune diseases. The compositions include polymeric particles of α-ketoglutarate to facilitate a slow and sustained release of therapeutic agents. The compositions block glycolysis in specific immune cells while upregulating antigen specific Tregs and reducing proliferation of antigen specific TH17 and total T helper cells. Please see the published US nonprovisional application (US20220280557A1) for additional information.
 
M19-241L – Metabolism-based CAR Therapies. Compositions which include reprogrammed antigen presenting cells such as macrophages (CAR-Macs), neutrophils (CAR-Neu), dendritic cells and T cells, that are metabolically fit in tumor environments. These compositions express CARs which are loaded with glycolysis accelerating metabolites. Please see the published US nonprovisional application (US20230265205A1) for additional information.
 
M19-223L - Metabolite Delivery for Modulating Metabolic Pathways of Cells. Compositions of metabolite-based polymeric particles for modulating intracellular metabolic-profile/pathways. These composition rescue immune cells against metabolic exhaustion by delivery of metabolites directly into the cells. Please see the published US nonprovisional application (US20220226499A1) for additional information.

Direct Link:
http://skysong.technologypublisher.com/tech/Metabolically-fit_Immunotherapies _Portfolio

Search Inventions

Looking for a technology or invention to commercialize? Arizona State University has more than 300 technologies available for licensing. Start your search here or submit your own invention.